CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 30 enrolled
Drug / intervention
Psilocybin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02950467
NCT02950467Phase 1Completed
CompareCT.gov

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

Joshua Woolley·interventional·Posted Nov 1, 2016·Updated Jan 7, 2021

In Brief

A Phase 1 clinical trial evaluating Psilocybin and Modified brief Supportive Expressive Group Therapy for Distress and 2 related conditions. Completed, enrolled 30 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDistress, Depression, Grief
CountriesUnited States
CollaboratorsHeffter Research Institute, RiverStyx Foundation, Usona Institute, Stupski Foundation

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 1, 2016
Enrollment StartJan 5, 2018
Primary CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 9.7 years ago

Interventions

Psilocybindrug

One individual oral psilocybin treatment session

Modified brief Supportive Expressive Group Therapybehavioral

Ten sessions of twice-weekly manualized group therapy